Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Elanco Animal Health Inc
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-95.3% vs price
Base Case (Median)
-93.6% vs price
Bull Case (75th pct.)
-79.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.64 | -97.1% | High (40%) |
| EV/EBITDA | $1.42 | -93.6% | Medium (20%) |
| EV/FCF | $7.47 | -66.3% | Medium (20%) |
Based on 3 out of 7 methods, ELAN appears overvalued at the current price of $22.14. The base case fair value of $1.42 implies 93.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.